Key result
PET/CT with [18F] FDG is valuable for staging, assessing chemotherapy response, predicting outcomes, detecting recurrence, and guiding biopsy in primary bone tumours.
Why the study?
Primary malignant bone tumours present diagnostic and therapeutic challenges due to inter-tumour heterogeneity, and the evolving role of PET imaging in their management requires critical summarization.
Does PET imaging improve the management of primary bone tumours?
Does PET imaging improve the management of primary bone tumours?
PET/CT with [18F] FDG provides valuable clinical utility in the comprehensive management of primary bone sarcomas, despite some limitations.
Supports FDG-PET/CT in primary bone tumour workflows; leaves open prospective validation before routine adoption.
Primary malignant bone tumours can pose significant diagnostic and therapeutic challenges due to inter-tumour heterogeneity. While traditional imaging modalities such as radiography, MRI (magnetic resonance imaging), and CT (computed tomography) remain essential for initial evaluation and staging, emerging evidence underscores the evolving role of positron emission tomography (PET), particularly PET/CT with Fluorodeoxyglucose ([18F] FDG), in the comprehensive management of bone sarcomas. This narrative review aims to critically summarise the available literature on PET imaging's utility in the management of primary bone tumours including osteosarcoma, chondrosarcoma, and Ewing sarcoma. Despite limitations like inconsistencies in standard uptake value (SUV) cutoffs and reduced pulmonary resolution, PET/CT is valuable for staging, assessing response to neoadjuvant chemotherapy, predicting histological outcomes, detecting recurrence, and guiding biopsy in metabolically active tumour sites. Further large-scale, prospective studies are warranted to standardise protocols and establish PET's definitive role in sarcoma management.
No takes yet. Share an insight, caveat, or question.
Suvarna et al. (2025) conducted a review in Primary bone tumours (osteosarcoma, chondrosarcoma, Ewing sarcoma). Positron emission tomography (PET) imaging, particularly PET/CT with [18F] FDG vs. Traditional imaging modalities (radiography, MRI, CT) was evaluated. PET/CT with [18F] FDG is valuable for staging, assessing chemotherapy response, predicting outcomes, detecting recurrence, and guiding biopsy in primary bone tumours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: